Dosing & Administration
Convenient at-home application with flexibility to fit your patient's routine1
Patients from birth to
<3 years of age:
2 syringes
for each weekly application1
Patients 3 years
and older:
4 syringes
for each weekly application1
VYJUVEK application is optimized for
weekly use2
"Longer intervals between VYJUVEK treatments may result in portions of healed wounds not receiving molecular correction." — Paller et al, 2024
VYJUVEK can be applied in the course of routine bandage changes at home by an HCP, patient, or caregiver1
VYJUVEK gel is applied in droplets that are evenly spaced (1 cm x 1 cm apart) on the selected wound in a grid pattern1
After application, patients may remove their VYJUVEK dressings as part of their next routine bandage change1
VYJUVEK should be applied to wounds weekly until they are closed1
Treated wounds may reopen and treatment should be prioritized to area that recently closed for retreatment with VYJUVEK2
What to expect with VYJUVEK2
The standard of care for healing DEB wounds:
Often, the initial areas selected are wounds that most impact the patient's daily activities, regardless of size.
It's important to set reasonable expectations with your patients about time to wound closure, especially given variability—areas of higher friction/impact and larger wounds may require prolonged treatment compared to smaller wounds and/or wounds in low-trauma areas.
Considerations
- Blisters can be treated
- Consider prioritizing hands and feet to reduce the risk of deformity/loss of function
- VYJUVEK can be used post-surgically (e.g., between fingers and around the ports of G-tubes following insertion)
- Diaper area may be prioritized in young patients to prevent long-term wounding and scarring
- Absence of skin at birth (Bart syndrome) should be a high priority to prevent long-term wound complications
VYJUVEK works best when wound care, skin infections, nutrition, anemia, and itch are all properly addressed.
Watch these videos to learn how to prepare and administer VYJUVEK
Get your patients started on VYJUVEK with Krystal Connect™ patient support
Get StartedVYJUVEK is a topical gel indicated for the treatment of wounds in adult and pediatric patients (from birth) with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene.
WARNINGS AND PRECAUTIONS
Accidental Exposure to VYJUVEK gel: VYJUVEK will not replicate in the subject’s cells and does not integrate into the subject cells’ native genetic material. For precautions, avoid direct contact with treated wounds (e.g., touching or scratching) and dressings of treated wounds until the next dressing change following treatment. Wear protective gloves when assisting patients with changing wound dressings and handling the disposal. In the event of accidental exposure (e.g., through a splash to the eyes or mucous membranes), flush with clean water for at least 15 minutes.
Clean all surfaces that may have come in contact with VYJUVEK biological suspension or gel and treat all spills with a virucidal agent.
Dispose all materials (e.g., vial, syringe, cleaning materials) that may have come in contact with VYJUVEK biological suspension or gel into a biohazard container.
ADVERSE REACTIONSThe most common adverse reactions (>5%) were itching, chills, redness, rash, cough, and runny nose.
- Please see Important Safety Information above and click here for full Prescribing Information.
1. VYJUVEK [prescribing information]. Krystal Biotech, Inc.; 2023.
2. Paller AS, Guide SV, Deigo A, et al. Practical considerations relevant to treatment with the gene therapy beremagene geperpavec-svdt for dystrophic epidermolysis bullosa. J Dermatolog Treat. 2024;35(1):2350232. doi:10.1080/09546634.2024.2350232
VYJUVEK is a topical gel indicated for the treatment of wounds in adult and pediatric patients (from birth) with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene.
WARNINGS AND PRECAUTIONS
Accidental Exposure to VYJUVEK gel: VYJUVEK will not replicate in the subject’s cells and does not integrate into the subject cells’ native genetic material. For precautions, avoid direct contact with treated wounds (e.g., touching or scratching) and dressings of treated wounds until the next dressing change following treatment. Wear protective gloves when assisting patients with changing wound dressings and handling the disposal. In the event of accidental exposure (e.g., through a splash to the eyes or mucous membranes), flush with clean water for at least 15 minutes.
Clean all surfaces that may have come in contact with VYJUVEK biological suspension or gel and treat all spills with a virucidal agent.
Dispose all materials (e.g., vial, syringe, cleaning materials) that may have come in contact with VYJUVEK biological suspension or gel into a biohazard container.
ADVERSE REACTIONSThe most common adverse reactions (>5%) were itching, chills, redness, rash, cough, and runny nose.
- Please see Important Safety Information above and click here for full Prescribing Information.
1. VYJUVEK [prescribing information]. Krystal Biotech, Inc.; 2023.
2. Paller AS, Guide SV, Deigo A, et al. Practical considerations relevant to treatment with the gene therapy beremagene geperpavec-svdt for dystrophic epidermolysis bullosa. J Dermatolog Treat. 2024;35(1):2350232. doi:10.1080/09546634.2024.2350232
You are about to leave the VYJUVEKHCP.com website
Are you sure you want to leave?